Abstract
Co-trimoxazole is an effective antibacterial agent for the prophylaxis of urinary tract infection. Because experimental evidence raises the possibility that high-dose cotrimoxazole might interfere with normal somatic growth, the longitudinal growth and growth velocities were analysed in 114 girls receiving long-term, low-dose prophylactic cotrimoxazole. They were aged 2–12 years at the start of prophylaxis which was given in a daily dose of approximately 10 mg sulphamethoxazole (SMX) and 2 mg trimethoprim (TMP)/kg body weight for at least 6 months and for up to 6 years.
There was no significant variation from normal in height or weight attained or in growth velocity overall in 114 girls, 51 of whom had vesico-ureteric reflux (VUR). No difference was found in growth velocity when periods of 6 months on or off prophylactic therapy were compared in 53 girls. Growth did not vary between cohorts of girls receiving co-trimoxazole prophylaxis for 2, 3 or 4 years and growth proceeded normally in the 51 girls with VU reflux.
We have not found evidence that long-term, low-dose co-trimoxazole prophylaxis has any adverse effect upon somatic growth in girls with a previous urinary infection with or without vesico-ureteric reflux and who are otherwise healthy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Finn JD (1972) Multivariance: Univariate and multivariate analysis of variance, covariance and regression. Ann Arbor: Michigan, National Education Resources
Forbes PA, Drummond KN (1973) Trimethoprim-sulfamethoxazole in recurrent urinary tract infection in children. J Infect Dis 128:626–628
Hills M, Armitage P (1979) The two-period cross-over clinical trial. British Journal of Clinical Pharmacology 8:7–20
Hitching GH (1969) Species differences among dihydrofolate reductases as a basis for chemotherapy. Postgrad Med J [Suppl] 45:7–10
Merrell RW, Mowad JJ (1979) Increased physical growth after successful antireflux operation. J Urol 122:523–527
Normand ICS, Smellie JM (1965) Prolonged maintenance chemotherapy in the management of urinary infection in childhood. British Medical Journal 1:1023–1026
O'Grady F, Kelsey Fry I, McSherry A, Cattell WR (1973) Long-term treatment of persistent or recurrent urinary tract infection with trimethoprim-sulphamethoxazole. J Infect Dis 128:652–656
Paton AM, Bernstein LS (1981) Some aspects of possible adverse reactions reported after co-trimoxazole therapy. In: Nordbring F, Burman LG (eds) Urinary tract infections. Almquist and Wiksell Internat. Stockholm, p 95
Smellie JM, Grüneberg RN, Leakey A, Atkin WS (1976) Long-term low-dose co-trimoxazole in prophylaxis of childhood urinary tract infection. British Medical Journal 2:203–206
Smellie JM, Katz G, Grüneberg RN (1978) Controlled trial of prophylactic treatment in childhood urinary tract infection. Lancet 2:175–178
Smellie JM, Grüneberg RN, Normand ICS, Bantock H (1982) Trimethoprim-sulfamethoxazole and trimethoprim alone in the prophylaxis of childhood urinary tract infection. Reviews of Infectious Diseases 4:461–466
Tanner JM, Whitehouse RH, Takaishi M (1966) Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965-I and-II. Arch Dis Child 41: 454–471, 613–635
Udall V (1969) Toxicology of sulphonamide-trimethoprim combinations. Postgrad Med J [Suppl] 45:42–45
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smellie, J.M., Preece, M.A. & Paton, A.M. Normal somatic growth in children receiving low-dose prophylactic co-trimoxazole. Eur J Pediatr 140, 301–304 (1983). https://doi.org/10.1007/BF00442669
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00442669